Dr Anthony Béhin (University Hospitals Pitié Salpêtrière, Paris, France) discusses highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of myasthenia gravis.
Disclosures: Anthony Béhin is a consultant for Alexion, Argenx, UCB, Sanofi and Ultragenyx pharmaceutical. He has received grant/research support from the Association Institut de Myologie and is on the advisory board for Alexion, Argenx, UCB, Sanofi and Ultragenyx pharmaceutical. He has received honoraria/honorarium from Alexion, Argenx, UCB, Sanofi and Ultragenyx. pharmaceutical
Support: Interview and filming was supported by Touch Medical Media. The interview was conducted by Sophie Nickelson.
Filmed as highlight of EAN 2023.
